Under the High Patronage of Mr Emmanuel MACRON President of the French Republic







Tuesday 7 November

Plenary ses	sion I	16:00-18:45
Chaine Inena N	australt (Dalainus) and Vandan Vandanaanah (Fuanaa)	Amphitheatre Bordeaux
	orstedt (Belgium) and Yazdan Yazdanpanah (France)	16:00-17:00
Opening cer		
	Yazdan Yazdanpanah, ANRS Maladies Infectieuses Emergentes/Insern ar Country Committee (France)	
	Iliana Ivanova, European Commissioner for Innovation, Research, Culture (Video presentation)	e, Education and Youth
	Laurent Muschel, acting Director General, Health Emergency and Respor European Commission	nse Authority (HERA),
	Tedros Adhanom Ghebreyesus, Director General, World Health Organisation (Video pro	
	Maria da Graça Carvalho, Member of the European Parliament (Video pro	
	Matshidiso Rebecca Moeti, Regional Director, World Health Organisation	n Africa Regional Office
	Jean Kaseya, Director General, Africa Centres for Disease Control and Pre	evention (Africa CDC)
Dr Pascoal N	locumbi keynote address	17:00-17:25
Disruptive se	cientific excellence and leadership for a better world	
•	Michel Kazatchkine, Senior Fellow, Global Health Center, the Graduate In	stitute for International
	Affairs and Development (Switzerland)	
Dr Pascoal N	Mocumbi Prize	17:25-17:45
Presenters:	Marcel Tanner (Switzerland) and Sonia Mocumbi (Mozambique)	
Welcome me	essage	17:45-18:00
	Henning Gädeke, Chair of the EDCTP Association and Chair of the Gover Health EDCTP3 Joint Undertaking (Germany)	ning Body of the Global
	Sylvie Retailleau, Minister of Higher Education and Research (France)	
Outstanding	Female Scientist Prize	18:00-18:15
Presenter:	Sylvie Retailleau (France)	
Keynote add		18:15-18:45
	versary Presentation: EDCTP 20 years and beyond – from I numbers to sustainable impact	
strategy and	Michael Makanga, Executive Director, EDCTP Association (The Netherlan	ds)
Cultural per	formance	18:45-19:00
	·	
Welcome co	cktail reception	19:00-20:45

Wednesday 8 November

The PANdem		
	ic Preparedness PlaTform for Health and Emerging Infections' Re	Room 34° Sponse (PANTHER)
Organiser(s):	PANTHER (France)	<u>, , , , , , , , , , , , , , , , , , , </u>
Presentations:	What could 80% ready tools look like?	
	Nathalie Strub Wourgaft, PANTHER (France)	
	Could regulators be better prepared?	
	Margareth Ndomondo-Sigonda, AUDA-NEPAD (Ethiopia)	
	Preparing for a new flu pandemic: yes we can Bernards Ogutu, Kenya Medical Research Institute (KEMRI, Kenya)	
	Preparing for phase 2 clinical trials: the need for more Phase 1 units i Salim Abdulla, Ifakara Health Institute (IHI, Tanzania)	n Africa
1.1 Worksh	an	08:00-09:0
	-r	Room 342
Global Healt	n EDCTP3: Presenting the new programme and its opportunities for	or collaboration
Organiser(s):	Global Health EDCTP3 Joint Undertaking (Belgium)	
Plenary sess	sion II	09:05-10:0
		Amphitheatre Bordeau
	anner (Switzerland)	I
	ress It from COVID-19 – and other infectious diseases – positioning Cellence in global health in the post-COVID-19 era	09:05-09:4
	Salim Abdool Karim, Centre for the AIDS Program of Research in South Af Africa)	rica (CAPRISA, South
	Affica)	
EDCTP Outst	anding Research Team Prize	09:45-10:0
EDCTP Outst Presenter:		09:45-10:00
Presenter:	anding Research Team Prize	09:45-10:00 10:00-10:30
Presenter:	anding Research Team Prize	
Presenter: Break	anding Research Team Prize Hannah Akuffo (Sweden)	10:00-10:3 10:30-12:3
Presenter: Break 1.1 Parallel	anding Research Team Prize Hannah Akuffo (Sweden)	10:00-10:3 10:30-12:3
Presenter: Break 1.1 Parallel Coinfections	anding Research Team Prize Hannah Akuffo (Sweden) session	
Presenter: Break 1.1 Parallel Coinfections Chairs: Marleer	anding Research Team Prize Hannah Akuffo (Sweden) session and comorbidities Temmerman (Kenya) and Johanna Schaefer (The Netherlands) Clinically relevant enantiomer specific R- and S-praziquantel pharmac interactions with efavirenz and ritonavir: Implications for HIV and schinfection	10:00-10:3 10:30-12:3 Room 34 cokinetic drug-drug nistosomiasis co-
Presenter: Break 1.1 Parallel Coinfections Chairs: Marleer OA-092	anding Research Team Prize Hannah Akuffo (Sweden) session and comorbidities Temmerman (Kenya) and Johanna Schaefer (The Netherlands) Clinically relevant enantiomer specific R- and S-praziquantel pharmae interactions with efavirenz and ritonavir: Implications for HIV and schinfection Roslyn Thelingwani, African Institute of Biomedical Science and Technology	10:00-10:30 10:30-12:30 Room 34 cokinetic drug-drug nistosomiasis co-
Presenter: Break 1.1 Parallel Coinfections Chairs: Marleer OA-092	Anding Research Team Prize Hannah Akuffo (Sweden) Session and comorbidities Temmerman (Kenya) and Johanna Schaefer (The Netherlands) Clinically relevant enantiomer specific R- and S-praziquantel pharmae interactions with efavirenz and ritonavir: Implications for HIV and schinfection Roslyn Thelingwani, African Institute of Biomedical Science and Technolog Reactivation of oncogenic herpesviruses is associated with co-infection	10:00-10:3 10:30-12:3 Room 34 cokinetic drug-drug nistosomiasis co- gy (Zimbabwe) ons causing severe
Presenter: Break 1.1 Parallel Coinfections Chairs: Marleer OA-092	anding Research Team Prize Hannah Akuffo (Sweden) session and comorbidities Temmerman (Kenya) and Johanna Schaefer (The Netherlands) Clinically relevant enantiomer specific R- and S-praziquantel pharmae interactions with efavirenz and ritonavir: Implications for HIV and schinfection Roslyn Thelingwani, African Institute of Biomedical Science and Technology	10:00-10:3 10:30-12:3 Room 34 cokinetic drug-drug nistosomiasis co- gy (Zimbabwe) ons causing severe n, South Africa
Presenter: Break 1.1 Parallel Coinfections Chairs: Marleer OA-092 OA-102	Anding Research Team Prize Hannah Akuffo (Sweden) Session and comorbidities Temmerman (Kenya) and Johanna Schaefer (The Netherlands) Clinically relevant enantiomer specific R- and S-praziquantel pharmac interactions with efavirenz and ritonavir: Implications for HIV and schinfection Roslyn Thelingwani, African Institute of Biomedical Science and Technolog Reactivation of oncogenic herpesviruses is associated with co-infectic inflammatory presentations in HIV-infected patients from Gugulethu Georgia Schafer, International Centre for Genetic Engineering and Biotech Africa) Myocardial structure and function assessed by cardiac magnetic reso with perinatal-acquired HIV infection taking antiretroviral therapy	10:00-10:3 10:30-12:3 Room 34 cokinetic drug-drug nistosomiasis co- gy (Zimbabwe) cons causing severe n, South Africa nology (ICGEB, South
Presenter: Break 1.1 Parallel Coinfections	Anding Research Team Prize Hannah Akuffo (Sweden) Session and comorbidities Temmerman (Kenya) and Johanna Schaefer (The Netherlands) Clinically relevant enantiomer specific R- and S-praziquantel pharmae interactions with efavirenz and ritonavir: Implications for HIV and schinfection Roslyn Thelingwani, African Institute of Biomedical Science and Technology Reactivation of oncogenic herpesviruses is associated with co-infection inflammatory presentations in HIV-infected patients from Gugulethur Georgia Schafer, International Centre for Genetic Engineering and Biotech Africa) Myocardial structure and function assessed by cardiac magnetic reso	10:00-10:3 10:30-12:3 Room 34 cokinetic drug-drug nistosomiasis co- gy (Zimbabwe) cons causing severe n, South Africa nology (ICGEB, South nance in adolescents

	Andrew Peter Kyazze, Makerere University (Uganda)	Jganda and Tanzania	
OA-901	Comorbidities in children and adolescents growing up with HIV: the need to focus beyond		
	viral suppression	,	
	Rashida Ferrand, London School of Hygiene and Tropical Medicine (UK) and	d Biomedical Research	
	and Training Institute (Zimbabwe)		
		10:30-12:3	
1.2 Parallel	session	Room 342	
Emerging in	fectious diseases & surveillance		
Chairs: Peter S	mith (United Kingdom) and Pauline Beattie (The Netherlands)		
OA-195 Spatial clustering, hotspot analysis and temporal distribution of the seve Disease outbreak in Uganda		eventh Ebola Virus	
	George Paasi, Mbale Clinical Research Institute (Uganda)		
OA-235	Antibody responses to endemic coronaviruses in South Africa		
	Rubina Bunjun, University of Cape Town (South Africa)		
OA-333	Kinetics of antibody in Ebola survivors following specific anti-Ebola tre	eatment in the	
	Democratic Republic of the Congo		
	Antoine Nkuba Ndaye, Institut National de Recherche pour le Développem	ent (France)	
OA-544	T cell responses to SARS-CoV-2 infection and vaccination in people liv		
	Wendy Burgers, University of Cape Town (South Africa)	g	
OA-652	Safety and tolerability of favipiravir for the treatment of Lassa fever: a	randomized	
	controlled open label phase II clinical trial		
	Mirjam Groger, Bernhard Nocht Institute for Tropical Medicine (BNITM, Germany)		
OA-801	Surveillance of respiratory viruses in Gabon during the COVID-19 pand		
	Georgelin Nguema Ondo, Centre de Recherches Médicales de Lambaréné (
<mark>1.3 Parallel</mark> Strengthenii	ng the ethics and regulatory framework	Room 342	
	e Singh (South Africa) and Nuraan Fakier (South Africa)		
OA-053	Using technology to build a regulatory ecosystem across Africa to help	streamline regulator	
	approval timelines, so doing, unlocking more investment into the continent		
~	Adriaan Kruger, NuvoteO (South Africa)	tinent	
OA-087	Adriaan Kruger, NuvoteQ (South Africa) Research ethics committees in Mozambigue: operational and function.		
OA-08/	Research ethics committees in Mozambique: operational and function		
OA-087	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019		
	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique)	al characteristics	
	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluations.	al characteristics	
	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluation project in the Portuguese-speaking African countries	al characteristics ation of the BERC-Lus	
OA-442	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluation project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Por	al characteristics ation of the BERC-Lus	
OA-442	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Portuguese) Contribution of the BREEDSAFCA project to the sustainable evolution	al characteristics ation of the BERC-Lus	
OA-442	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Portuguese) Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon	al characteristics ation of the BERC-Lus rtugal) of research	
OA-442 OA-510	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Portibution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroon)	al characteristics ation of the BERC-Lus rtugal) of research	
OA-442 OA-510	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Potentibution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national	
OA-442 OA-510	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Poleon Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national	
OA-442 OA-510 OA-713	Research ethics committees in Mozambique: operational and functional evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Potential Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal)	al characteristics ation of the BERC-Luse rtugal) of research n) nt for the national ch Ethics Committee	
OA-442 OA-510	Research ethics committees in Mozambique: operational and functions evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Pot Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national ch Ethics Committee	
OA-442 OA-510 OA-713	Research ethics committees in Mozambique: operational and functions evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Pote Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research management system for research ethics and regulation in Uganda	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national ch Ethics Committee	
OA-442 OA-510 OA-713	Research ethics committees in Mozambique: operational and functions evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Pot Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national ch Ethics Committee	
OA-442 OA-510 OA-713 OA-721	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Poteon Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research management system for research ethics and regulation in Uganda Maxwell Otim Onapa, Busitema University (Uganda)	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national rch Ethics Committee h information	
OA-442 OA-510 OA-713	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Poteon Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research management system for research ethics and regulation in Uganda Maxwell Otim Onapa, Busitema University (Uganda)	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national rch Ethics Committee h information	
OA-442 OA-510 OA-713 OA-721	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Poteon Contribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research management system for research ethics and regulation in Uganda Maxwell Otim Onapa, Busitema University (Uganda)	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national rch Ethics Committee h information	
OA-442 OA-510 OA-713 OA-721 Networking	Research ethics committees in Mozambique: operational and functions evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Potentibution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research management system for research ethics and regulation in Uganda Maxwell Otim Onapa, Busitema University (Uganda)	al characteristics ation of the BERC-Luse rtugal) of research n) nt for the national rch Ethics Committee h information	
OA-442 OA-510 OA-713 OA-721 Networking	Research ethics committees in Mozambique: operational and functions evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Potentibution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroo Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research management system for research ethics and regulation in Uganda Maxwell Otim Onapa, Busitema University (Uganda)	al characteristics ation of the BERC-Lus rtugal) of research n) nt for the national ch Ethics Committee	
OA-442 OA-510 OA-713 OA-721	Research ethics committees in Mozambique: operational and function evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique) Legislative, educational, training, institutional and social impact evaluate project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Potentribution of the BREEDSAFCA project to the sustainable evolution participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroote Achieving the ISO9001 certification: a milestone in quality management research ethics committee: the case of the Senegalese National Resear Samba Cor Sarr, Health Research Authority (Senegal) Leveraging digital platforms to support a sustainable national research management system for research ethics and regulation in Uganda Maxwell Otim Onapa, Busitema University (Uganda)	al characteristics ation of the BERC-Luse rtugal) of research n) nt for the national rch Ethics Committee h information	

1.2 Worksł	пор	13:00-13:45
		Room 341
WHO's Clini	cal Trial Resolution: Better Evidence, a Stronger Ecosystem	
Organiser:	Vasee Moorthy, Senior Advisor, WHO Science Division (Switzerland)	

Organiser:	Vasee Moorthy, Senior Advisor, WHO Science Division (Switzerland)	
1 1 Colombie	14:00-15:30	
1.1 Scientii	ic symposia Room 341	
Ensuring that partnership	t Children with HIV in Africa survive and thrive: Celebrating the CHAPAS 4 trial	
Organiser:	University College London (United Kingdom)	
Chairs:	Victor Musiime (Uganda) and Bwendo Nduna (Zambia)	
Presentations:	Optimising metabolic and bone health in Children living with HIV	
	Mutsa Bwakura-Dangarembizi, University of Zimbabwe (Zimbabwe)	
	Pharmacokinetics of drugs for second-line antiretroviral therapy among children and adolescents living with HIV	
	Hylke Waalewijn, University of Cape Town (South Africa)	
	Capacity strengthening through 'hub-and-spoke' within-country mentoring of new research centres, and training early career researchers in Africa and Europe, leveraging on a clinical trial network	

14:00-15:30 1.2 Scientific symposia Room 342A Partnerships for implementation research to optimise the impact of Seasonal Malaria

Chemoprevention in West and Central Africa: the OPT-SMC project

Veronica Mulenga, University of Zambia (Zambia)

Chemopreven	oprevention in west and Central Africa. the OFT-Swic project	
Organiser:	Université de Thiès (Senegal)	
Chairs:	Jean-Louis Ndiaye (Senegal) and Corinne Merle (Switzerland)	
Presentations:	Regional partnerships for strengthening implementation research to improve access to SMC	
	Jean-Louis Ndiaye, Université de Thiès (Senegal)	
	Scaling-up of SMC in Nigeria: community perceptions and public engagement, a qualitative study in 5 States	
	Nnenna Ogbulafor, National Malaria Elimination Programme (Nigeria)	
	Barriers to SMC access in urban areas in Burkina Faso and strategies to improve uptake	
	Aissata Barry, Programme National de Lutte contre le Paludisme (Burkina Faso)	
	Scaling-up of SMC in Guinea: adapting strategies in hard-to-reach populations	
	Bienvenu Camara, Maferinyah Research Centre (Guinea)	
	Evaluating three strategies to improve adherence to SMC in Mali	
	Mady Cissoko/Aissata Kone, Programme National de Lutte contre le Paludisme (Mali)	
	Summary and forward look for the control of seasonal malaria	
	Fatimata Sall, Université de Thiès (Senegal)	

1.3 Scientifi	c symposia	14:00-15:30 Room 342B
A paradigm shift towards local and gender balanced leadership, promoting equitable partnerships and next generation African leaders, PAMAfrica-SINDOFO case studies		
Organiser:	Centro de Investigação em Saúde de Manhiça (CISM, Mozambique)	
Chairs:	Rella Zoleko Manego (Gabon) and Innocent Valea (Burkina Faso)	
Presentations:	Capacity building, shifting the paradigm of traditional North-South co fostering equitable partnerships and building an African leadership Charles S Mgone, former Executive Director of EDCTP (Tanzania) (Video pre	•

What is takes to enhance an equitable and sustainable research in Africa, a case study of an innovative clinical trial delivery

Ghyslain Mombo-Ngoma, Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon)

Career progression in clinical research for future leaders, addressing gender and opportunity challenges through advanced degree and practical training to enrich African clinical trial ecosystem

Dearie Okwu, PhD student, CERMEL (Gabon) and Jessica Dalsuco, PhD student, CISM (Mozambique)

Break		15:30-16:00
Plenary ses	ssion III	16:00-17:15
Ana Lúcia Ca Preventing	andya (The Netherlands) and Marleen Temmerman (Kenya) ardoso Weinberg keynote address maternal deaths, care and prevention of severe complications of and early life: The interaction between infectious and non-ble diseases Claudia Hanson, Karolinska Institutet (Sweden)	16:00-16:25
complicatio	enting maternal deaths, care and prevention of severe ns of pregnancy and early life, addressing disparities in outcomes and babies from different population groups	16:25-17:15
Speakers:	 arleen Temmerman, Aga Khan University (Kenya) Barbara Kerstiëns, European Commission Esperança Sevene, Eduardo Mondlane University (Mozambique) Jean-Paul Dossou, Centre de Recherche en Reproduction Humaine et en (CERRHUD, Benin) Philippe Van de Perre, Université de Montpellier (France) 	Démographie
Break		17:15-17:45
	esearchers of PALOP: health science research in the Portuguese rican countries	17:45-18:45 Room 341
Presenters:	 Martin Essayan, Calouste Gulbenkian Foundation (Portugal) (Video prese HRH Infanta Cristina of Spain Eusebio Macete, Manhiça Health Research Centre (CISM, Mozambique) Angola: Claudia Videira, Centro de Investigação de Saúde de Angola Cabo Verde: Neidy Rodrigues, Universidade de Cabo Verde Guinea Bissau: Baltazar Cá, Instituto Nacional de Saúde Publica (INASA) Mozambique: Nilsa de Deus, Instituto Nacional De Saúde (INS) 	ntation)
Meet the Ed	litors	17:45-18:45 Room 342A
Chairs: Michell Presenters:	 e Helinski (The Netherlands) and Moses Bockarie (Sierra Leone) Zoë Mullan, Editor-in-Chief, The Lancet Global Health, Inclusion & Divers Group (United Kingdom) Marco De Ambrogi, Deputy Chief Editor of Lancet Infectious Diseases (Ur 	•

• David Ofori-Adjei, Editor-in-Chief, Ghana Medical Journal (Ghana) (Virtual participation)

• João Monteiro, Chief Editor, Nature Medicine (United States)

Thursday, 9 November

•	and Allied Sciences e s, costs, and lessons ya portunities
The Global Health Network (United Kingdom) Satellite session Perspectives on the pilot implementation of the first malaria value of PATH (United States) Evelyn Ansah (Ghana) Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccine Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccine	and Allied Sciences s, costs, and lessons ya portunities
Perspectives on the pilot implementation of the first malaria van PATH (United States) Evelyn Ansah (Ghana) Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccine Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccine	Room 342. and Allied Sciences e s, costs, and lessons ya portunities)
Perspectives on the pilot implementation of the first malaria value. PATH (United States) Evelyn Ansah (Ghana) Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccine Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccine	and Allied Sciences s, costs, and lessons ya portunities
Perspectives on the pilot implementation of the first malaria value. PATH (United States) Evelyn Ansah (Ghana) Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccine Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccine	and Allied Sciences s, costs, and lessons ya portunities
PATH (United States) Evelyn Ansah (Ghana) Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccin Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccin	and Allied Sciences e s, costs, and lessons ya portunities)
Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccin Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccin	s, costs, and lessons ya portunities
Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccin Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccin	s, costs, and lessons ya portunities
Introduction Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccin Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccin	s, costs, and lessons ya portunities
Professor Evelyn Ansah, Centre for Malaria Research, University of Health (Ghana) Background to the Pilot Implementation of the RTS,S Malaria Vaccine Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccine	s, costs, and lessons ya portunities
Mary Hamel, World Health Organization Learning by Doing: A public health sector perspective on the benefit learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccin	s, costs, and lessons ya portunities
learned from the pilot implementation of the malaria vaccine in Ken Rose Jalang'o, National Vaccines and Immunizations Programme (Kenya) Nesting the Phase 4 in the Pilot Implementation: Challenges and opp Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccin	ya portunities)
Miloje Savic, Global Health Vaccines & Adjuvants, GSK Vaccines (Belgium When to Invest? The impact of market uncertainty on malaria vaccin)
•	e manufacturing
When to Invest? The impact of market uncertainty on malaria vaccine manufacturing Jonathan Hutchin, MedAccess (United Kingdom)	
Concluding remarks	
Evelyn Ansah, Centre for Malaria Research, University of Health and Allied	d Sciences (Ghana)
	00.05.40.0
n IV	09:05-10:0 Amphitheatre Bordeau
wal (Norway) and Mocos Rockario (Siorra Loone) (TRC)	Amphitheatre bordeau
	09:05-09:3
	03.03 03.3
<u> </u>	
<u> </u>	
Audience Q&A	
c Leadership Prize	09:45-10:0
	10:00-10:3
rsian	10:30-12:3
SSION	Room 34
tious diseases: diagnosis, treatment and prevention	
	mini direct on blood
	Concluding remarks Evelyn Ansah, Centre for Malaria Research, University of Health and Allied IV wal (Norway) and Moses Bockarie (Sierra Leone) (TBC) is conger institutions: what is making it happen? Abdoulaye Djimdé, University of Bamako (Mali) Audience Q&A c Leadership Prize Thomas Nyirenda (South Africa) ssion ctious diseases: diagnosis, treatment and prevention elinski (The Netherlands) and Michael Ramharter (Germany) Improved molecular diagnosis of visceral leishmaniasis (VL) using the PCR Nucleic Acid Lateral Flow Immunoassay (dbPCR-NALFIA)

Nelly Mwageni, Catholic University of Health and Allied Sciences (Tanzania)

Development of a CAA/CCA duplex test for improved diagnosis of human schistosomiasis

Skin diseases and their frequency patterns in skin camps in PEP4LEP implementing districts in

Henk Schallig, Academic Medical Center (Netherlands)

Tanzania, preliminary results

Pytsje Hoekstra, Leiden University Medical Center (Netherlands)

OA-196

OA-270

OA-445	A phase II/III multicenter randomized clinical trial evaluating the safety and efficacy of a single and three-day albendazole-ivermectin fixed-dose versus albendazole to treat soil-transmitted helminthiases Jose Muñoz, ISGLOBAL (Spain)
OA-504	Towards an arsenic-free oral treatment for human African trypanosomiasis due to <i>T.b.</i> rhodesiense: a new tool for disease elimination Olaf Valverde Mordt, Drugs for Neglected Diseases initiative (DNDi, Switzerland)
OA-765	Molecular diagnostic tests specificities and their contribution for HAT postelimination monitoring in Burkina Faso and Côte d'Ivoire Charlie Franck Alfred Compaoré, Institut de Recherche Pour Le Développement (Burkina Faso)

2.2 Paralle	el session	10:30-12:30
L.L I didii		Room 342A
Advances i	n drug development in TB and HIV	
Chairs: Jean N	Marie Habarugira (Belgium) and Aleksandra Conversano (Belgium)	
OA-083	Early bactericidal activity of meropenem, ertapenem, amoxicillin/clavurifampicin in pulmonary tuberculosis Caryn Upton, TASK (South Africa)	llanate and optimized
OA-225	Optimising second line anchor drug options for children with HIV in Arthe CHAPAS-4 randomised trial Abbas Lugemwa, Joint Clinical Research Centre (Uganda)	frica: 96-week results of
OA-286	Plasma concentrations of first line antituberculosis drugs in infants wit pneumonia: a pharmacokinetic sub-study of the EMPIRICAL trial Chishala Chabala, University of Zambia, School of Medicine (Zambia)	th HIV and severe
OA-451	Spirometry, diffusion capacity, absolute lung volumes and PET/CT find of tuberculosis treatment – preliminary findings of StatinTB/ExtendTB Friedrich Thienemann, University of Cape Town (South Africa)	
OA-770	Treatment outcomes of low-level viremia among adults living with HIV first line antiretroviral therapy in Botswana Ontlametse T Bareng, Botswana Harvard AIDS Institute (Botswana)	V on dolutegravir-based
OA-739	High-levels of HIV drug resistance persist in ART-experienced patients rollout in KwaZulu-Natal, South Africa Aabida Khan, Department of Virology, University of KwaZulu-Natal, Durban	

2.3 Parall	el session	10:30-12:30 Room 342B
Capacity st	trengthening	
Chairs: Thom	nas Nyirenda (South Africa) and Lydia Boudarene (Belgium)	
OA-252	East and Southern African Consortium for Outbreak Epidemiology Trai Emily Webb, London School of Hygiene & Tropical Medicine (LSHTM, Unite	
OA-322	Bridging the research gaps on AMR in sub-Saharan Africa – a One Heal Rea Kobialka, Institute of Animal Hygiene and Veterinary Public Health, Univ (Germany)	• •
OA-345	The 1,000 global research studies challenge: developing nursing, midw health workers' research leaders to transform global healthcare Trudie Lang, University of Oxford (United Kingdom)	ifery and community
OA-365	Capacity building as a response to emerging and re-emerging infection Peter Olupot-Olupot, Mbale Clinical Research Institute / Busitema University presentation)	
OA-408	Clinical trial capacity building from scratch: the WANECAM 2 experient Abdoulaye Djimde, WANECAM 2 – University of Science, Techniques and Te (Mali)	
OA-686	Advancing research on epidemic prone-pathogens: "Integrated Service Outbreak Research" (ISIDORe) Jonathan Ewbank, ERINHA (Belgium)	es for Infectious Disease
Networkin	g lunch	12:30-14:00

Poster prese	entations – B	12:45-14:0
2.2 Worksh	non	13:00-13:4
LIL WOTKS	. .	Room 342
	ope: Funding opportunities for your infectious disease research pr	ojects and meet the
	European contact points for health to help you	
Organiser:	Health-NCP-Net 3.0 (HNN 3.0)	
2.4 Parallel	session	14:00-16:0 Room 34
Advances in	vaccines & neutralising antibodies development	ROOM 54
	Viebig (Germany) and Christine Stabell Benn (Denmark)	
OA-240	Determining whether mass vaccination campaigns with fractional-dos could accelerate group protection against pneumococcal transmission Issaka Soumana, Epicentre (Niger)	
OA-344	Clinical development in Burkina Faso of novel malaria vaccines based Jordan Plieskatt, Statens Serum Institut (Denmark)	on the Pfs48/45 antiger
OA-490	Safety, reactogenicity and immunogenicity of MTBVAC in newborns in a TB endemic area: a phase 2a randomized, double-blind, dose-defining trial	
OA-498	Ingrid Murillo Jelsbak, Biofabri SLU (Spain) PedMAb1 clinical trial: Safety assessment of CAP256V2LS to prevent breastmilk HIV transmission in HIV-1 exposed uninfected neonates Gabriella Scarlatti, IRCCS Occadalo San Paffaelo (Italy)	
OA-722	Gabriella Scarlatti, IRCCS Ospedale San Raffaele (Italy) Assessment of naturally acquired humoral immunity against malaria protecting against controlled human malaria infection (CHMI) Naubaup Parry, University of Tübingen (Corporat)	
OA-779	Nouhoun Barry, University of Tübingen (Germany) Beneficial non-specific effects of oral polio vaccinations campaigns – did one drop save mor lives than anyone could have imagined? Sebastian Nielsen, University of Southern Denmark (Denmark)	
		14:00-16:0
2.5 Parallel	session	Room 342
Advancing t	he development and implementation of TB diagnostics	
Chairs: Debora	Bade (The Netherlands) and Marieke van der Werf (Sweden)	
OA-068	Implementation of integrated health-checks for TB-affected households in Zimbabwe Claire Calderwood, Biomedical Research and Training Institute (BRTI) & London School of Hygiene and Tropical Medicine (LSHTM, Zimbabwe)	
OA-208	Evaluating the impact of computer-assisted x-ray diagnosis and other triage tools to optimise Xpert orientated community-based active case finding for TB and COVID-19 (XACT-19) Alex Scott, Centre for Lung Infection and Immunity, University of Cape Town Lung Institute (South Africa)	
OA-272	Health system costs of decentralized TB diagnostic testing with Molbio Truenat MTB/RIF vs. hub-and-spoke GeneXpert MTB/RIF in Mozambique and Tanzania	
OA-464	Akash Malhotra, Johns Hopkins University (United States) Clinical predictors of tuberculosis in children – a prospective study in five low-middle income countries Laura Olbrich, Ludwig-Maximilians-University (Germany)	
OA-484	Improving rapid detection of 2nd line drug resistance in Mycobacterium tuberculosis with Xpert MTB/XDR and MolBio 2nd line Bouke De Jong, Institute of Tropical Medicine (Belgium)	
OA-724	Interrogation of an multi drug resistant tuberculosis outbreak using w	hole genome

2.6 Parallel	session	14:00-16:00 Room 342B
Community e	engagement	
	Fakier (South Africa) and <i>TBC</i>	
OA-097	Facilitators and barriers to infant HIV post-natal prophylaxis (PNP), a qualitative sub-study of the PROMISE-EPI trial in Lusaka, Zambia Anaïs Mennecier, Université de Montpellier (France)	
OA-271	Stakeholders' perspectives and willingness on use of SMS reminders and mobile money incentives to reduce loss to follow-up among presumptive TB patients in Uganda Esther Buregyeya, Makerere University School of Public Health (Uganda)	
OA-506	Working towards better guidance for studies that involve African healthy volunteers in the context of the VolREthics initiative Esperança Sevene, Eduardo Mondlane University (Mozambique)	
OA-601	Acceptability of the future introduction of intermittent preventive treatment for malaria in infants in Massinga district, Mozambique Neusa Torres, Manhiça Health Research Centre (CISM, Mozambique)	
OA-667	HIV self-testing uptake and linkage to HIV care among male fisherfolk in two fishing communities in rural Uganda: early results from the PEST4MEN study Joseph KB Matovu, Makerere University School of Public Health (Uganda)	
OA-815	A community approach to re-thinking the principles of good randomize informative, respectful, collaborative, feasible and well-managed Rachel Hallett, The Good Clinical Trials Collaborative (GCTC, United Kingdom)	
Break		16:00-16:30
2.1 Scientifi		16:30-18:00 Room 341
	nostics accessible – beyond diagnostic platforms and assays	
Organiser:	Foundation for Innovative New Diagnostics (FIND, Switzerland)	
Chairs: Presentations:	Katharina Kranzer (United Kingdom) and Alberto Garcia-Basteiro (Spain) A diagnostic testing algorithm for inpatients living with HIV – the TB-0 Marta Cossa, Manhiça Health Research Centre (Mozambique)	CAPT EXULTANT trial
	Real life implementation of Molbio Truenat by the National TB Prograworks and what does not work Immaculate Kathure, Ministry of Health (Kenya)	m in Kenya – _what
	Improving access to new TB diagnostic tools in Africa: bridging the res	search to national policy
	Marguerite Massinga Loembe, African Society for Laboratory Medicine (ASL	_M, Ethiopia)
	Lessons learned from the XPEL-TB trial assessing the effectiveness and streamlined strategy for delivery of Xpert Ultra testing Achilles Katamba, Makerere University (Uganda) (Video presentation)	implementation of a
	Implementation of the Xpert MTB/XDR diagnostic test into routine lab South Africa; key strategies to overcome challenges Pedro da Silva, National Priority Programmes (NPP, South Africa)	ooratory algorithms in
	Implementation of the Molbio Truenat/MTB Assays at Primary Health Mozambique - the TB-CAPT CORE trial Celso Khosa, Instituto Nacional de Saúde (INS, Mozambique)	Centers in Tanzania and
	Making diagnostics accessible – beyond diagnostic platforms and assa Panel discussion	ys
2.2 Scientifi	c symposia	16:30-18:00 Room 342A

From the ben	ch to the field: contextual complexities in access and delivery of new health
technologies	in African health systems
Organiser:	University of Health and Allied Sciences (Ghana)
Chairs:	Jürg Utzinger (Switzerland)
Presentations:	African health research systems and Early-Stage Research and Development of innovative health technologies
	Olumide Ogundahunsi, University of Medical Sciences (Nigeria)
	Health system readiness and Implementation Research to support the access and delivery of new health technologies in Africa
	Margaret Gyapong, University of Health and Allied Sciences (Ghana)
	Capacity building in readiness for implementation and public health impact
	Garry Aslanyan, TDR the Special Programme for Research and Training in Tropical Diseases (Switzerland)
	Regulatory Frameworks and Policies to support the access and delivery of new health technologies
	Cecilia Oh, UNDP Access and Delivery Partnership (Thailand)

2.3 Scientifi	c symposia	16:30-18:00 Room 342B
_	ard impactful clinical trials through collaborative research in sub- ne EDCTP NoEs	Saharan Africa: The
Organiser:	EDCTP Regional Networks of Excellence and The Global Health Network (Ur	nited Kingdom)
Chairs:	Souleymane Mboup (Senegal), Francine Ntoumi (Congo) and Bernard Kikaire (Uganda)	
Presentations:		
	The New Ecosystem for health research and data science, why, for whom and when Frank Kagoro/Elvis Temfack, TGHN (Tanzania/United Kingdom), Africa CDC (Ethiopia/Cameroon) Empowering Girls and Women in Science Careers in Africa: Action by NoEs NoEs	
Global Health	EDCTP3 networking dinner	19:00

Friday 10 November

3.1 Sponsor	ed satellite session	08:00-09:00 Room 341
Nothing less	than health for all: Essential elements for sustainable NTD contro	
_	lical innovation	
Organiser:	Drugs for Neglected Diseases initiative (DNDi, Switzerland)	
Presentations:	Introduction and welcome	
	Luis Pizarro, DNDi (Switzerland)	
	Innovative R&D and built capacity for the elimination of sleeping sic Florent Mbo, HAT Platform/DNDi (Democratic Republic of Congo)	kness
	Visceral leishmaniasis: on the brink of game-changing treatment opt Ahmed M. Musa, Institute of Endemic Diseases, University of Khartoum (S	
	Helminths: Partnering for the pipeline Coralie Martin, Muséum National d'Histoire Naturelle (France)	
	Nothing less than health for all – what is at stake when we talk about	t partnership and
	innovation for NTDs Spring Gombe, Market Access Africa (Switzerland)	
3.1 Worksh	ор	08:00-09:00
		Room 342A
	ative Clinical Trials: The DAC-A Story	
Organiser:	Global Health Strategies (United States)	
Dlanamy	ion V	09:05-10:15
Plenary sess	SION V	Amphitheatre Bordeaux
Chair: Catherine	e Hankins (Canada)	
	ualities in Global Health	09:05-10:15
Moderator:	Catherine Hankins, McGill University (Canada)	l .
 Speakers: Nkando Luo, Global One Health Institute, Lusaka Environmental Health Univ Margaret Gyapong, University of Health and Allied Sciences (UHAS, Ghana) Magda Robalo Correia Silva, Institute for Global Health and Development (0 Francisco Saúte, Director General of the Manhiça Health Research Centre (C 		ana) ent (Guinea-Bissau)
Break		10:15-10:45
3.1 Parallel	session	10:45-12:30 Room 341
Partnerships		ROOM 541
	ndya (The Netherlands) and Richard Adegbola (Nigeria)	
OA-059		s evnerienced and
OA 033	Achieving equitable leadership in Global Health partnerships: barriers experienced and strategies to improve grant funding for early and mid-career researchers in low- and middle-income countries	
	Toyin Togun, London School of Hygiene and Tropical Medicine (LSHTM, U	Jnited Kingdom)
OA-217	Introducing a priority review voucher in the EU to encourage neglect	ted disease product
	development	
04.050	Agustin Martin Lasanta, Deutsche Stiftung Weltbevoelkerung (DSW, Belgi	
OA-358	Innovative access approach to translate R&D into impact for prescho	ool-aged children
	suffering from schistosomiasis	Commons) Include
	Beatrice Greco, ARES Trading SA, an affiliate of Merck KGaA, Darmstadt (C	ermany) - on behalf of
OA-533	Pediatric Praziquantel Consortium UKCDR: enhancing coherence, collaboration, and joint action in the U	IK rocoarch funding
OA-355	landscape and beyond Maggy Heintz, UK Collaborative on Development Research (UKCDR, Unite	_
	iviaggy meintz, ok conaborative on bevelopment Research (OKCDR, Unite	eu Kiliguolli)

OA-902	Empower African R&D stakeholders to advance equitable and sustain health products: toward policy recommendations Raffaella Ravinetto, Institute of Tropical Medicine (ITM, Belgium)	ned access to quality
3.2 Paralle	session	10:45-12:30 Room 342A
Maternal ar	nd child health	KOUIII 342F
	errat Blazquez-Domingo (The Netherlands) and Andiswa Zitho (South Africa)	
OA-058	Associations between prenatal malaria exposure, maternal antibodies susceptibility during the first year of life in Burkina Faso Hamtandi Magloire Natama, Institu de Recherche en Sciences de la Sante Clinique de Nanoro (Burkina Faso)	
OA-099	Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: a multi-centre, double-blind, placebo-controlled trial (MAMAH project) Raquel González, Barcelona Institute for Global Health (Spain)	
OA-183	Dynamic of molecular and resistance markers prevalence of <i>Plasmodium falciparum</i> during the seasonal malaria chemoprevention campaign in school aged children in Bandiagara, Mal Karim Traoré, Malaria Research and Training Center, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB, Mali) (<i>Video presentation</i>)	
OA-218	Enhanced effect of seasonal malaria chemoprevention when coupled with nutrients supplementation for preventing malaria in children under five years old in Burkina Faso Paul Sondo, Institut de Recherche en Sciences de la Santé/Clinical Resaerch Unit of Nanoro (Burkina Faso)	
OA-429	High mortality in African infants living with HIV hospitalized with sev Bwendo Nduna, Arthur Davison Children's Hospital (Zambia)	vere pneumonia
OA-715	Receipt of intravenous co-amoxiclav challenges eligibility screening for Johannesburg, South Africa David Moore, University of the Witwatersrand (South Africa)	for the PediCAP Trial in
3.3 Paralle	l session	10:45-12:30 Room 342I
Capacity sti	rengthening	1.00111 3 121
Chairs: Miche	le Nderu (South Africa) and Debora Bade (The Netherlands)	
OA-189	Building capacity for HIV cure research in Ghana - The H-CRIS Experi George Kyei, University of Ghana (Ghana)	ence
OA-098	Creating a whole that is more than the sum of its parts: an emerging clinical trial units in UK, West and East Africa Armel Zemsi, Medical Research Unit The Gambia at the London School of	collaboration between
		Hygiene & Tronical
	Medicine (The Gambia) (Video presentation)	Hygiene & Tropical
OA-900	Medicine (The Gambia) (Video presentation) A bilingual training platform in data management and sharing to supacross the EDCTP Networks of Excellence Aboutakar Soma Centre MURAZ National Institute of Public Health (Burl	pport open science
OA-900 OA-903	A bilingual training platform in data management and sharing to supacross the EDCTP Networks of Excellence Aboubakar Soma, Centre MURAZ, National Institute of Public Health (Burl Breaking Barriers, Bridging Knowledge: Inclusion of Women in clinical Addressing Gender and Diversity Regional Gaps in Clinical Research Communications.)	pport open science kina Faso) al research by Capacity in Africa
OA-903	A bilingual training platform in data management and sharing to supacross the EDCTP Networks of Excellence Aboubakar Soma, Centre MURAZ, National Institute of Public Health (Burl Breaking Barriers, Bridging Knowledge: Inclusion of Women in clinical	pport open science kina Faso) al research by Capacity in Africa mbia (Zambia)
OA-903 OA-904	A bilingual training platform in data management and sharing to supacross the EDCTP Networks of Excellence Aboubakar Soma, Centre MURAZ, National Institute of Public Health (Burl Breaking Barriers, Bridging Knowledge: Inclusion of Women in clinical Addressing Gender and Diversity Regional Gaps in Clinical Research (Mwansa Ketty Lubeya, University Teaching Hospitals, The University of Zal Role of Pathogen Genomics in Public Health: Lessons from HIV and Copandemic preparedness Sikhulile Moyo, Botswana Harvard AIDS Institute Partnership (Botswana)	pport open science kina Faso) al research by Capacity in Africa mbia (Zambia)
	A bilingual training platform in data management and sharing to supacross the EDCTP Networks of Excellence Aboubakar Soma, Centre MURAZ, National Institute of Public Health (Burl Breaking Barriers, Bridging Knowledge: Inclusion of Women in clinical Addressing Gender and Diversity Regional Gaps in Clinical Research (Mwansa Ketty Lubeya, University Teaching Hospitals, The University of Zal Role of Pathogen Genomics in Public Health: Lessons from HIV and Copandemic preparedness Sikhulile Moyo, Botswana Harvard AIDS Institute Partnership (Botswana)	pport open science kina Faso) al research by Capacity in Africa mbia (Zambia) COVID-19 towards
OA-903 OA-904 Networking	A bilingual training platform in data management and sharing to supacross the EDCTP Networks of Excellence Aboubakar Soma, Centre MURAZ, National Institute of Public Health (Burl Breaking Barriers, Bridging Knowledge: Inclusion of Women in clinical Addressing Gender and Diversity Regional Gaps in Clinical Research (Mwansa Ketty Lubeya, University Teaching Hospitals, The University of Zal Role of Pathogen Genomics in Public Health: Lessons from HIV and Copandemic preparedness Sikhulile Moyo, Botswana Harvard AIDS Institute Partnership (Botswana)	pport open science kina Faso) al research by Capacity in Africa mbia (Zambia) COVID-19 towards

Plenary se	ssion VI	14:00-15:40
Plenary se	221011 A1	Amphitheatre Bordeaux
Panel: Glob	al Health EDCTP3: strategy and links with other global initiatives	14:00-15:00
Moderator: Pa	auline Beattie (The Netherlands) and Thomas Nyirenda (South Africa)	
Speakers:	John Gyapong, Adjunct Professor of Global Health, Georgetown University	sity, USA; Chairperson of
	the Scientific Committee of the Global Health EDCTP3 Joint Undertaking (Ghana)	
	• Nevena Miletic, Policy Head EMEA, Global Regulatory Policy at F. Hoffmann-La Roche and Co-	
	Chair of IFPMA's African Regulatory Network (Switzerland)	
	Lindiwe Makubalo, Assistant Regional Director, World Health Organisation Africa Regional Office	
	Jean Kaseya, Director General, Africa Centres for Disease Control and Pr	revention (Africa CDC)
		15.00 15.40
Closing ceremony		15:00-15:40
	Harleen Grewal, Forum Scientific Programme Committee Chair and EDCTF	Scientific Advisory
	Committee Chair (Norway)	
	Michael Makanga, EDCTP Association (The Netherlands)	
	Tunji Alausa, Minister of State, Health and Social Welfare (Nigeria)	
	Anne-Claire Amprou, the French Ambassador for Global Health	